Search results
Bristol-Myers Squibb Expected to Earn Q2 2024 Earnings of $1.76 Per Share (NYSE:BMY)
ETF DAILY NEWS· 12 hours agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Equities research analysts at Leerink Partnrs lowered their Q2 2024 EPS estimates for shares of Bristol-Myers Squibb in a report issued on Thursday ...
Why Bristol Myers Squibb Stock Is Sinking Today
Motley Fool via Yahoo Finance· 4 days agoShares of Bristol Myers Squibb (NYSE: BMY) were down 8.3% as of 11:19 a.m. ET on Thursday. The sell-off came after the big drugmaker announced its...
Repertoire partners with Bristol Myers for autoimmune vaccines By Investing.com
Investing.com· 3 hours agoRepertoire Immune Medicines, a biotech firm specializing in T cell targeted immune therapies, has...
Bristol-Myers stock falls despite Q1 beat (NYSE:BMY)
Seeking Alpha· 4 days agoBristol-Myers Squibb (BMY) stock dips even as the company topped consensus with Q1 2024 results, despite headwinds in its growth portfolio. Read more...
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to...
FOX 4 Kansas City· 4 hours agoRepertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year ...
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts
InvestorPlace· 4 days agoBristol-Myers Squibb (NYSE:BMY) layoffs are a hot topic on Thursday after the biopharmaceutical...
Merck and Bristol-Myers Squibb are bracing to lose their most lucrative patents
Quartz· 4 days agoPharma giants Merck and Bristol-Myers Squibb are both getting ready for some of their key drug...
Is Bristol Myers Squibb Stock a Millionaire Maker?
Motley Fool via Yahoo Finance· 4 days agoMany top healthcare stocks provide investors with long-term stability, promising growth prospects, and in some cases even a dividend. Yet, investors...
Bristol Myers pays $65M to expand Repertoire of autoimmune assets
FierceBiotech· 4 hours agoBristol Myers Squibb is placing a $65 million bet on Repertoire Immune Medicines’ approach to resetting the immune system. Repertoire, a Flagship-founded biotech that underwent a major reset ...
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Benzinga via Yahoo Finance· 4 days agoThursday, Bristol Myers Squibb & Co (NYSE:BMY) posted first-quarter revenues of $11.9 billion,...